CB Technologies Releases Report on Use of EDC; Survey Shows Increased Use Of Electronic Data Capture Software by Life Science Organizations

Apr 30, 2001, 01:00 ET from CB Technologies, Inc.

    EXTON, Pa., April 30 /PRNewswire/ -- Today, CB Technologies, Inc. releases
 the results of its second annual industry survey on the use of EDC technology
 by pharmaceutical and related companies.  It indicates that life science
 companies are increasingly embracing new technology tools that streamline data
 collection processes during clinical trials.  CB is the premier provider of
 clinical electronic data capture (EDC) software and support services.
     "This year's survey results overwhelmingly show that life science
 organizations are serious about adopting technologies that increase
 productivity and bring more efficient processes to the time-consuming job of
 collecting and analyzing clinical trial data," says James L. Coyne, CEO of CB.
 "Process improvement via technology has become mission critical to
 pharmaceutical and related companies as they focus on improved time to market,
 competitive advantage and increased shareholder value."
     CB surveyed more than 1200 pharmaceutical, biotechnology, contract
 research organizations and academic research centers.  The survey received
 109 respondents from seven countries, including Canada, France, Germany,
 Italy, Sweden, the United Kingdom and the United States.
 
     Industry Acceptance
     Of the companies surveyed, responses were positive regarding EDC use:
      -- 64% of respondents are currently using or have used EDC technology
          for clinical trials.
      -- 63% have had positive or neutral experiences with EDC while only 11%
          report having had a negative experience.
      -- 35% plan to use an EDC system for clinical trials within the next
          18 months.
 
     It's clear from the survey results that life science organizations are now
 seeing bottom-line benefits to EDC.  Respondents indicated they felt that EDC
 generates revenue by helping get products to market faster (27%), saves on the
 costs associated with a trial (5%) or both (36%).
     Regarding the type of system companies are considering, 30% favor a hybrid
 (online/offline) system, 29% indicated they are looking at a thin-client (Web-
 only) system, and 18% are considering a client/server system.
     "To my knowledge, CB is the only firm in this sector performing and
 responding to such a user survey," says Ellen Semple, CB's vice president,
 marketing.  "Working closely with our own product's users (MetaTrial(TM)), and
 understanding and responding to market needs is a cornerstone of CB's success.
 It's our goal to streamline user acceptance by offering a robust solution that
 diminishes potential concerns such as performance, security and ease of use."
 
     Areas for Improvement
     Life science companies still have some hesitations with implementing EDC
 systems.  Among the greatest concerns:
      -- 70% of respondents cite user acceptance as the top concern.
      -- 61% cite system performance as a key issue.
      -- 61% name integration with existing systems as a concern.
 
     CB's survey also gauged the industry's interest in integrated solutions
 including interactive voice response and personal digital assistants among
 others.
     For a copy of CB Technologies' EDC Survey Report, email info@cbtech.com.
 
     About CB Technologies, Inc.
     CB Technologies, Inc. is a leading provider of Electronic Clinical
 Intelligence(TM) tools and services for the life science industries. CB is
 headquartered in Philadelphia with offices in Boston, New York, Charleston,
 San Francisco, San Diego and London.  For more information visit our website
 at www.cbtech.com or www.metatrial.com.
     CB Technologies, MetaTrial, Electronic Clinical Intelligence, eCI and EDC
 Unplugged are trademarks of CB Technologies, Inc.  All other company names and
 products may be the property of their respective owners.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X97742815
 
 

SOURCE CB Technologies, Inc.
    EXTON, Pa., April 30 /PRNewswire/ -- Today, CB Technologies, Inc. releases
 the results of its second annual industry survey on the use of EDC technology
 by pharmaceutical and related companies.  It indicates that life science
 companies are increasingly embracing new technology tools that streamline data
 collection processes during clinical trials.  CB is the premier provider of
 clinical electronic data capture (EDC) software and support services.
     "This year's survey results overwhelmingly show that life science
 organizations are serious about adopting technologies that increase
 productivity and bring more efficient processes to the time-consuming job of
 collecting and analyzing clinical trial data," says James L. Coyne, CEO of CB.
 "Process improvement via technology has become mission critical to
 pharmaceutical and related companies as they focus on improved time to market,
 competitive advantage and increased shareholder value."
     CB surveyed more than 1200 pharmaceutical, biotechnology, contract
 research organizations and academic research centers.  The survey received
 109 respondents from seven countries, including Canada, France, Germany,
 Italy, Sweden, the United Kingdom and the United States.
 
     Industry Acceptance
     Of the companies surveyed, responses were positive regarding EDC use:
      -- 64% of respondents are currently using or have used EDC technology
          for clinical trials.
      -- 63% have had positive or neutral experiences with EDC while only 11%
          report having had a negative experience.
      -- 35% plan to use an EDC system for clinical trials within the next
          18 months.
 
     It's clear from the survey results that life science organizations are now
 seeing bottom-line benefits to EDC.  Respondents indicated they felt that EDC
 generates revenue by helping get products to market faster (27%), saves on the
 costs associated with a trial (5%) or both (36%).
     Regarding the type of system companies are considering, 30% favor a hybrid
 (online/offline) system, 29% indicated they are looking at a thin-client (Web-
 only) system, and 18% are considering a client/server system.
     "To my knowledge, CB is the only firm in this sector performing and
 responding to such a user survey," says Ellen Semple, CB's vice president,
 marketing.  "Working closely with our own product's users (MetaTrial(TM)), and
 understanding and responding to market needs is a cornerstone of CB's success.
 It's our goal to streamline user acceptance by offering a robust solution that
 diminishes potential concerns such as performance, security and ease of use."
 
     Areas for Improvement
     Life science companies still have some hesitations with implementing EDC
 systems.  Among the greatest concerns:
      -- 70% of respondents cite user acceptance as the top concern.
      -- 61% cite system performance as a key issue.
      -- 61% name integration with existing systems as a concern.
 
     CB's survey also gauged the industry's interest in integrated solutions
 including interactive voice response and personal digital assistants among
 others.
     For a copy of CB Technologies' EDC Survey Report, email info@cbtech.com.
 
     About CB Technologies, Inc.
     CB Technologies, Inc. is a leading provider of Electronic Clinical
 Intelligence(TM) tools and services for the life science industries. CB is
 headquartered in Philadelphia with offices in Boston, New York, Charleston,
 San Francisco, San Diego and London.  For more information visit our website
 at www.cbtech.com or www.metatrial.com.
     CB Technologies, MetaTrial, Electronic Clinical Intelligence, eCI and EDC
 Unplugged are trademarks of CB Technologies, Inc.  All other company names and
 products may be the property of their respective owners.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X97742815
 
 SOURCE  CB Technologies, Inc.